The Impact of Plasma Protein Binding Characteristics and Unbound Concentration of Voriconazole on Its Adverse Drug Reactions.

albumin protein binding rate unbound drug concentration voriconazole α1-acid glycoprotein

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2020
Historique:
received: 22 08 2019
accepted: 31 03 2020
entrez: 12 5 2020
pubmed: 12 5 2020
medline: 12 5 2020
Statut: epublish

Résumé

This study investigated voriconazole (VRC) unbound plasma concentration and its relationship with adverse drug reactions (ADRs) in patients with malignant hematologic disease. Plasma samples were collected from patients or spiked

Identifiants

pubmed: 32390847
doi: 10.3389/fphar.2020.00505
pmc: PMC7194128
doi:

Types de publication

Journal Article

Langues

eng

Pagination

505

Informations de copyright

Copyright © 2020 Yuan, Qiao, Yang, Yu, Sun, Qian, Zhang, Meng, Zhang and Wang.

Références

World J Gastroenterol. 2015 Jan 21;21(3):711-25
pubmed: 25624707
Clin Transplant. 2016 Nov;30(11):1377-1386
pubmed: 27581783
Enferm Infecc Microbiol Clin. 2015 May;33(5):298-302
pubmed: 25459191
J Pharm Sci. 2014 Aug;103(8):2565-70
pubmed: 24961809
Yakugaku Zasshi. 2013;133(6):711-7
pubmed: 23558910
J Microbiol Immunol Infect. 2018 Apr;51(2):260-266
pubmed: 27329132
Drug Discov Today. 2012 May;17(9-10):475-85
pubmed: 22210121
Ther Drug Monit. 2014 Dec;36(6):752-8
pubmed: 24819971
Antimicrob Agents Chemother. 2014 Nov;58(11):6782-9
pubmed: 25182655
Clin Pharmacokinet. 2013 Jan;52(1):1-8
pubmed: 23150213
Clin Rheumatol. 2017 Mar;36(3):609-615
pubmed: 27376754
Front Pharmacol. 2019 Jul 30;10:854
pubmed: 31417408
Pharmacogenet Genomics. 2017 May;27(5):190-196
pubmed: 28306618
Clin Drug Investig. 2008;28(5):263-79
pubmed: 18407713
Drug Metab Dispos. 2003 Jun;31(6):731-41
pubmed: 12756205
Drug Metab Dispos. 2016 Jan;44(1):124-6
pubmed: 26502771

Auteurs

Zi-Qing-Yun Yuan (ZQ)

Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Chun Qiao (C)

Hematology Department, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Zhi-Cheng Yang (ZC)

Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Lei Yu (L)

Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Lu-Ning Sun (LN)

Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Yi Qian (Y)

Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Xue-Hui Zhang (XH)

Department of Pharmacy, the Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou, China.

Ling Meng (L)

Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Xiao-Yan Zhang (XY)

Hematology Department, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Yong-Qing Wang (YQ)

Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Department of Pharmacy, the Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou, China.

Classifications MeSH